Hyundai Bioscience Co (XKRX:048410) Net Change in Cash : ₩405 Mil (TTM As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Hyundai Bioscience Co's Net Change in Cash for the three months ended in Mar. 2024 was ₩2,053 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was ₩405 Mil.

Hyundai Bioscience Co Net Change in Cash Historical Data

The historical data trend for Hyundai Bioscience Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Net Change in Cash Chart

Hyundai Bioscience Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

2,392.76

13,659.97

-10,026.27

-6,456.41

-920.55

Hyundai Bioscience Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															726.73	1,132.64	-1,189.83	-1,590.07	2,052.66

Hyundai Bioscience Co Net Change in Cash Calculation

Hyundai Bioscience Co's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-6008.319	+	5177.464	+	-57.966	+	-31.724
	=	-921

Hyundai Bioscience Co's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -7808.728 + 9888.433 + 21.743 + -48.785

= 2,053

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩405 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyundai Bioscience Co Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Hyundai Bioscience Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyundai Bioscience Co (XKRX:048410) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Net Change in Cash

Comparable Companies

XKRX:145020 XKRX:086900 XKRX:214450 XKRX:141080 XKRX:096530 XKRX:085660 XKRX:016790 XKRX:064550 XKRX:298380 XKRX:005250 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

N/A

Address

150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR

Website

http://www.hyundaibioscience.com

Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines